Characteristic | Estimate (95% CI) | P |
---|---|---|
Intercept | 10.4 (10.2, 10.5) | <0.001 |
Hospital type (Ref = general) | ||
 Specialized | 0.2 (0.1, 0.2) | <0.001 |
Age at diagnosis (years) (Ref = ≥65) | ||
 <45 | 0.0 (−0.1, 0.1) | 0.419 |
 45–54 | 0.1 (0.0, 0.2) | 0.131 |
 55–64 | 0.0 (−0.1, 0.1) | 0.522 |
Sex (Ref = women) | ||
 Men | 0.0 (−0.1, 0.1) | 0.969 |
Education (Ref = primary school or below) | ||
 Junior high school | 0.0 (−0.1, 0.1) | 0.815 |
 Senior high school | 0.0 (0.0, 0.1) | 0.310 |
 Undergraduate or higher | 0.1 (0, 0.2) | 0.134 |
Occupation (Ref = self-employee or unemployee) | ||
 Farmer | 0.0 (−0.1, 0.2) | 0.493 |
 Enterprise or company employee/worker | −0.1 (−0.2, 0.0) | 0.057 |
 Retiree | 0.1 (−0.1, 0.2) | 0.377 |
 Public sector employee | 0.2 (0.1, 0.3) | 0.004 |
 Other | 0.0 (−0.3, 0.2) | 0.778 |
Healthcare insurance type (Ref = new rural cooperative medical scheme) |  |  |
 Urban employee basic medical insurance | 0.0 (−0.1, 0.1) | 0.641 |
 Urban resident basic medical insurance | 0.0 (−0.1, 0.1) | 0.707 |
 Commercial insurance | 0.0 (−0.3, 0.4) | 0.792 |
 Self-paid | 0.0 (−0.2, 0.2) | 0.905 |
 Other | 0.4 (0.1, 0.7) | 0.020 |
Previous-year household income (CNY) (Ref = ≤20,000) | ||
 20,000–39,999 | 0.1 (0.0, 0.2) | 0.006 |
 40,000–69,999 | 0.1 (0.0, 0.2) | 0.046 |
 ≥70,000 | 0.1 (0.0, 0.2) | 0.006 |
Clinical stage (Ref = I) | ||
 II | 0.0 (−0.1, 0.1) | 0.822 |
 III | 0.1 (0.0, 0.2) | 0.099 |
 IV | 0.3 (0.1, 0.4) | <0.001 |
Pathologic type (Ref = others) | ||
 Adenocarcinoma | 0.2 (0.1, 0.3) | <0.001 |
Therapeutic regimen (Ref = surgery) | ||
 Chemotherapy | 0.2 (0.1, 0.3) | <0.001 |
 Surgery and postoperative chemotherapy | 0.2 (0.1, 0.3) | <0.001 |
 Symptomatic treatment | 0.1 (0.0, 0.2) | 0.170 |
 Concurrent chemoradiotherapy | 0.8 (0.6, 1.0) | <0.001 |
 Radiotherapy | 0.5 (0.3, 0.7) | <0.001 |
 Neoadjuvant chemotherapy and surgery | 0.2 (−0.2, 0.6) | 0.251 |